As a result, the theoretical antitumor effect of dual PI3k/Akt/mTOR inhibitor NVP-BEZ235 was strongly repressed, manifesting as the resistant phenotype in RCC cells. The gene discussed is MTOR; the disease is renal cell carcinoma.